Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers

S. Veneroni, N. Zaffaroni, M. G. Daidone, E. Benini, R. Villa, R. Silvestrini

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The expression of P-glycoprotein (P-gp) was studied by immunocytohistochemistry, using the C219 monoclonal antibody, in 39 locally advanced breast cancers and 20 ovarian cancers from previously untreated patients. P-gp was expressed in 46 and 35% of breast and ovarian tumours, respectively. A significant association was observed in both tumour types between P-gp expression and in vitro resistance to doxorubicin. We also observed a higher clinical response rate to doxorubicin ± vincristine in patients with breast cancers not expressing P-gp. Conversely, no correlation was found between P-gp expression and in vitro resistance to cisplatin or in vivo response to cisplatin ± cyclophosphamide treatment in ovarian cancers. Our results support the relevance of P-gp expression as a specific indicator of resistance to certain drugs, such as doxorubicin and vincrinstine, involved in the phenomenon of multidrug resistance in breast and ovarian cancer cells.

Original languageEnglish
Pages (from-to)1002-1007
Number of pages6
JournalEuropean Journal of Cancer
Volume30
Issue number7
DOIs
Publication statusPublished - 1994

Fingerprint

P-Glycoprotein
Ovarian Neoplasms
Doxorubicin
Cisplatin
Breast Neoplasms
Multiple Drug Resistance
Vincristine
Cyclophosphamide
In Vitro Techniques
Monoclonal Antibodies
Pharmaceutical Preparations
Neoplasms

Keywords

  • breast cancer
  • chemosensitivity assays
  • doxorubicin
  • immunocytohistochemistry
  • multidrug resistance
  • ovarian cancer
  • P-glycoprotein

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. / Veneroni, S.; Zaffaroni, N.; Daidone, M. G.; Benini, E.; Villa, R.; Silvestrini, R.

In: European Journal of Cancer, Vol. 30, No. 7, 1994, p. 1002-1007.

Research output: Contribution to journalArticle

@article{e045f56cbfcd40c7bd1ea83bcfda9322,
title = "Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers",
abstract = "The expression of P-glycoprotein (P-gp) was studied by immunocytohistochemistry, using the C219 monoclonal antibody, in 39 locally advanced breast cancers and 20 ovarian cancers from previously untreated patients. P-gp was expressed in 46 and 35{\%} of breast and ovarian tumours, respectively. A significant association was observed in both tumour types between P-gp expression and in vitro resistance to doxorubicin. We also observed a higher clinical response rate to doxorubicin ± vincristine in patients with breast cancers not expressing P-gp. Conversely, no correlation was found between P-gp expression and in vitro resistance to cisplatin or in vivo response to cisplatin ± cyclophosphamide treatment in ovarian cancers. Our results support the relevance of P-gp expression as a specific indicator of resistance to certain drugs, such as doxorubicin and vincrinstine, involved in the phenomenon of multidrug resistance in breast and ovarian cancer cells.",
keywords = "breast cancer, chemosensitivity assays, doxorubicin, immunocytohistochemistry, multidrug resistance, ovarian cancer, P-glycoprotein",
author = "S. Veneroni and N. Zaffaroni and Daidone, {M. G.} and E. Benini and R. Villa and R. Silvestrini",
year = "1994",
doi = "10.1016/0959-8049(94)90132-5",
language = "English",
volume = "30",
pages = "1002--1007",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers

AU - Veneroni, S.

AU - Zaffaroni, N.

AU - Daidone, M. G.

AU - Benini, E.

AU - Villa, R.

AU - Silvestrini, R.

PY - 1994

Y1 - 1994

N2 - The expression of P-glycoprotein (P-gp) was studied by immunocytohistochemistry, using the C219 monoclonal antibody, in 39 locally advanced breast cancers and 20 ovarian cancers from previously untreated patients. P-gp was expressed in 46 and 35% of breast and ovarian tumours, respectively. A significant association was observed in both tumour types between P-gp expression and in vitro resistance to doxorubicin. We also observed a higher clinical response rate to doxorubicin ± vincristine in patients with breast cancers not expressing P-gp. Conversely, no correlation was found between P-gp expression and in vitro resistance to cisplatin or in vivo response to cisplatin ± cyclophosphamide treatment in ovarian cancers. Our results support the relevance of P-gp expression as a specific indicator of resistance to certain drugs, such as doxorubicin and vincrinstine, involved in the phenomenon of multidrug resistance in breast and ovarian cancer cells.

AB - The expression of P-glycoprotein (P-gp) was studied by immunocytohistochemistry, using the C219 monoclonal antibody, in 39 locally advanced breast cancers and 20 ovarian cancers from previously untreated patients. P-gp was expressed in 46 and 35% of breast and ovarian tumours, respectively. A significant association was observed in both tumour types between P-gp expression and in vitro resistance to doxorubicin. We also observed a higher clinical response rate to doxorubicin ± vincristine in patients with breast cancers not expressing P-gp. Conversely, no correlation was found between P-gp expression and in vitro resistance to cisplatin or in vivo response to cisplatin ± cyclophosphamide treatment in ovarian cancers. Our results support the relevance of P-gp expression as a specific indicator of resistance to certain drugs, such as doxorubicin and vincrinstine, involved in the phenomenon of multidrug resistance in breast and ovarian cancer cells.

KW - breast cancer

KW - chemosensitivity assays

KW - doxorubicin

KW - immunocytohistochemistry

KW - multidrug resistance

KW - ovarian cancer

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=0028023408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028023408&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)90132-5

DO - 10.1016/0959-8049(94)90132-5

M3 - Article

C2 - 7946563

AN - SCOPUS:0028023408

VL - 30

SP - 1002

EP - 1007

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -